Patents by Inventor Thomas Nitschke Kledal

Thomas Nitschke Kledal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FUSION TOXIN PROTEINS FOR TREATMENT OF DISEASES RELATED TO CMV INFECTIONS
    Publication number: 20220281933
    Abstract: The present invention relates to immunotoxins useful in treating diseases related to CMV infection. The invention also relates to use of the immunotoxin and pharmaceutical compositions comprising the immunotoxin as a medicament, and a kit for treatment or prevention of CMV infection comprising the immunotoxin.
    Type: Application
    Filed: June 25, 2020
    Publication date: September 8, 2022
    Inventors: Thomas Nitschke KLEDAL, Mette Marie ROSENKILDE
  • Immunotoxins for the treatment of diseases related to CMV infection
    Patent number: 8592554
    Abstract: The present invention relates to the field of cytomegalovirus (CMV) infection. In particular the present invention relates to highly specific immunotoxins useful in treating diseases related to CMV infection. CMV encodes chemokine receptors that undergo constitutive internalization. Thus CMV infected cells can be targeted specifically with immunotoxins with high affinity to CMV encoded constitutively internalizing receptors. This will ensure efficient uptake of the immunotoxin by the CMV infected cell, and thereby ensure the death of the infected cell with a minimum of unwanted toxicity and side effects. Furthermore, the invention relates to a way of inhibiting CMV replication and/or growth by using immunotoxins by targeting constitutively internalizing CMV encoded receptors.
    Type: Grant
    Filed: July 3, 2007
    Date of Patent: November 26, 2013
    Assignee: Inagen ApS
    Inventors: Thomas Nitschke Kledal, Mette M. R. Roed
  • IMMUNOTOXINS FOR THE TREATMENT OF DISEASES RELATED TO CMV INFECTION
    Publication number: 20100048470
    Abstract: The present invention relates to the field of cytomegalovirus (CMV) infection. In particular the present invention relates to highly specific immunotoxins useful in treating diseases related to CMV infection. CMV encodes chemokine receptors that undergo constitutive internalization. Thus CMV infected cells can be targeted specifically with immunotoxins with high affinity to CMV encoded constitutively internalizing receptors. This will ensure efficient uptake of the immunotoxin by the CMV infected cell, and thereby ensure the death of the infected cell with a minimum of unwanted toxicity and side effects. Furthermore, the invention relates to a way of inhibiting CMV replication and/or growth by using immunotoxins by targeting constitutively internalizing CMV encoded receptors.
    Type: Application
    Filed: July 3, 2007
    Publication date: February 25, 2010
    Inventors: Thomas Nitschke Kledal, Mette M.R. Roed